Weekly Patent Roundup

Weekly Patent Roundup

Darunavir in Swedish Preliminary Injunction Proceedings

Recently, the Paris High Court decided for a preliminary injunction against the commercialisation of Darunavir by Sandoz, the SPC Blog report can be found here. In parallel proceedings, the Swedish Patent and Market Appeal Court has come to the opposite conclusion, and found that that the contested SPC would most likely be found invalid and thus denied a request for a preliminary injunction. Hampus Rystedt from Zacco has kindly provided the following summary of the case…..

Report: Jury orders Takeda to pay Bayer $155M over hemophilia drug

A U.S. jury has ordered Takeda Pharmaceutical’s Baxalta unit to pay Bayer AG $155.19 million for infringing a patent related to a Baxalta hemophilia treatment. According to Reuters, jurors in the federal court in Wilmington, Del., reached their verdict on the seventh day of a trial after rejecting Baxalta’s argument that the June 2016 patent on the treatment, Adynovate, was invalid……

Roche denied India patent for powder formulation for anti-HIV drug Valcyte

In a setback to Swiss pharma major F Hoffmann-La Roche (Roche), the Indian patent office has rejected the company’s application for a powder formulation for Valganciclovir, its anti-viral drug for HIV patients sold under brand name Valcyte. The Chennai patent office refused the patent for the formulation on the ground of lack of novelty……

A Second Opposition Is Filed against Janssen’s Patent Application for the Fumarate Salt Form of Bedaquiline

Multiple news outlets recently reported about a pre-grant patent opposition filed by two TB survivors, with support from MSF, against a patent application filed by Janssen for a salt form of its experimental TB drug bedaquiline. In a press note put out by MSF, it was claimed that this opposition “…is the first ever challenge against a TB drug patent in India”. This is a factually incorrect statement…..

Diagnosis: Ineligible

Mayo is involved in another diagnostic method patent dispute — and again has come out on-top with a finding that the asserted patent claims are ineligible under 35 U.S.C. 101. That district court finding has now been affirmed on appeal, although subject to a strong dissent from Judge Newman……

Full Fed. Circ. Won’t Review $20M Cialis Marketing Verdict

The full Federal Circuit on Tuesday declined to review whether a panel erred by upholding a $20 million infringement verdict entered in Texas federal court against Eli Lilly & Co. for…

Fed Circuit refusal paves way for Suboxone generics

Rivals of British pharmaceutical company Indivior will soon be able to sell generic versions of opioid addiction treatment Suboxone film (buprenorphine and naloxone) following a ruling of the US Court of Appeals for the Federal Circuit….

Leave a Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2024 Pharma IP Circle. All Rights Reserved